Program
bafisontamab
Also written as “EMB-01”, “EMB-01 1600 mg administered once weekly throughout the study” and “EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter”.
Its studies are mostly in Colorectal Neoplasms · Neoplasm Metastasis · Carcinoma, Non-Small-Cell Lung · Neoplasms · Smoking Cessation, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai EpimAb Biotherapeutics | 44 open or running | phase 2since Dec 26, 2018 | Dec 26, 2018 | Dec 30, 2027phase 2 · NCT07314294 |
| Rose Research Center | 10 open or running | phase 3since Oct 5, 2020 | Oct 5, 2020 | none ahead |
Also a collaborator on its studies: labcorp-corporation-of-america-holdings-inc, covance and embera-neurotherapeutics-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 26, 2018First study: phase 2 study in NeoplasmsNew to Shanghai EpimAb BiotherapeuticsShanghai EpimAb Biotherapeutics · NCT03797391 · 186 planned · United States, China
- Oct 5, 2020Rose Research Center's first study: phase 3 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04868253 · 25 enrolled · United States
- Nov 3, 2021Phase 2 study in NeoplasmsShanghai EpimAb Biotherapeutics · NCT05176665 · 152 planned · United States, China
- Jun 28, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungShanghai EpimAb Biotherapeutics · NCT05498389 · 115 planned · United States, China
- Dec 4, 2025Phase 2 study in Colorectal NeoplasmsShanghai EpimAb Biotherapeutics · NCT07314294 · 54 planned · China
Ahead
- Dec 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsShanghai EpimAb Biotherapeutics · NCT07314294
TargetBeta
“A human, Fabs-in-tandem immunoglobulin (FIT-Ig)-based, tetravalent, bispecific antibody targeting both the epidermal growth factor receptor EGFR and the hepatocyte growth factor receptor (HGFR; cMet; c-Met), ”NCIt, by rule
“Hepatocyte growth factor receptor inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| amivantamabrule | Johnson & Johnson | phase 3 | 16 |
| HS-20117 | Hansoh Pharmaceutical Group | phase 3 | 3 |
| pamvatamigrule | Betta Pharmaceuticals | phase 2 | 5 |
| TQB2922 | Sino Biopharmaceutical | phase 2 | 5 |
| TQB6411 | Sino Biopharmaceutical | phase 2 | 3 |
| Anti-EGFR/Anti-c-Met Bispecific Antibody-drug Conjugate VBC101rule | VelaVigo Cayman | phase 2 | 1 |
| Anti-c-Met/EGFR/VEGF Trispecific Antibody TAVO412rule | tavotek-biotherapeutics | phase 1 | 2 |
| HS-20122 | Hansoh Pharmaceutical Group | phase 1 | 2 |
| Anti-EGFR/c-Met/c-Met-Topoisomerase-1 Inhibitor Trispecific Antibody-drug Conjugate BG-C0902rule | BeOne Medicines | phase 1 | 1 |
| Anti-EGFR/c-Met-CPT-113 Antibody-drug Conjugate JNJ-95437446 | Johnson & Johnson | phase 1 | 1 |
| HLX48 | Fosun Pharma | phase 1 | 1 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07314294Colorectal Neoplasms · China | 2 | Recruiting | Shanghai EpimAb Biotherapeutics | Dec 30, 2027 | 54 |
| NCT05498389Carcinoma, Non-Small-Cell Lung · United States, China | 2 | Not yet recruiting | Shanghai EpimAb Biotherapeutics | Jul 2024 | 115 |
| NCT05176665Neoplasms · United States, China | 2 | Recruiting | Shanghai EpimAb Biotherapeutics | Dec 31, 2025 | 152 |
| NCT04868253Smoking Cessation · United States | 3 | UNKNOWN | Rose Research Center | Dec 31, 2021 | 25 |
| NCT03797391Neoplasms · United States, China | 2 | Recruiting | Shanghai EpimAb Biotherapeutics | Mar 14, 2025 | 186 |
How it is read
Names in the registry
- “EMB-01”, 4 entries
- “EMB-01 1600 mg administered once weekly throughout the study”, 1 entry
- “EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Neoplasms, 1 study
- Smoking Cessation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.